Pharmaserve Lilly S.A.C.I
Pharmaserve Lilly S.A.C.I is recorded as a service provider in 16 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 16 of 16 trials · Latest update first
J6E-MC-KWAM: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event – ACCLAIM-Lp(a)
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
J2J-MC-JZLH EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
JS2-MC-GZMI: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Delaying Time to Relapse Compared with Placebo in Adult Participants with Major Depressive Disorder (RENEW-MDD- 2)
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
J2A-MC-GZPW: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
J2O-MC-EKBG: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event - MOVE-Lp(a)
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
I3Y-MC-JPEF: postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
J2A-MC-GZPL: A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION); J2A-MC-GZL1: Participants with Hypertension and Obesity or Overweight; J2A-MC-GZL2: Participants with Hypertension and Obesity or Overweight
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
I6T-MC-AMCE: A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered with Tirzepatide in Adult Participants with Moderately to Severely Active Crohn’s Disease and Obesity or Overweight
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
I4V-MC-JAJA (RA-BRIDGE): A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
J2G-MC-JZJC: LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
J2J-OX-JZLC: EMBER-3: A Phase 3, Randomized, Open-label Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Patients with Estrogen receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with endocrine Therapy
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
J1A-MC-KDAF: A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Peresolimab in Adult Participants with Moderately-to-Severely Active Rheumatoid Arthritis
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
I3Y-MC-JPBL: MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without abemaciclib, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Pharmaserve Lilly S.A.C.I?
The 2026-10-09 snapshot links Pharmaserve Lilly S.A.C.I to 16 distinct CTIS trials. Recorded services include Clinical monitoring, Payment services, Project management, Regulatory services, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Pharmaserve Lilly S.A.C.I?
The most frequently recorded therapeutic areas are Cardiology, Solid Tumor Oncology, Gastroenterology, Gynecology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Pharmaserve Lilly S.A.C.I conducted?
The linked trials record locations in 25 countries, including Greece, Spain, Italy, Poland, Belgium. These are trial locations, not confirmed office locations or countries where Pharmaserve Lilly S.A.C.I delivered services.
What can this page tell me about Pharmaserve Lilly S.A.C.I's trial experience?
Browse 16 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Pharmaserve Lilly S.A.C.I. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Pharmaserve Lilly S.A.C.I.